ATMP Symposium for Knowledge Exchange, Innovation, and Future Collaborations

Blog post by Carin Dahlberg, Scientific coordinator NextGenNK

On January 22, 2025, NextGenNK and CCRM Nordic hosted a mini-symposium at Karolinska Institutet, Campus Flemingsberg, with a focus on Advanced Therapy Medicinal Products (ATMP). The event aimed to foster networking within the ATMP field and provide insights into both academic and commercial advancements in Stockholm and Sweden.

NextGenNK and CCRM Nordic co-organized the mini-symposium to strengthen the development of ATMP by combining academic research with industrial expertise. During a half-day event, 14 presentations were delivered by representatives from academia, hospitals, and industry. Together, we aim to create a platform that facilitates innovation, production, and increased adoption of advanced therapies.

The event’s goal was to promote further collaboration and networking among researchers, clinicians, and industry partners, thereby supporting ongoing projects, contributing to the development of new initiatives, and increasing visibility for the ATMP field in Sweden. By bringing together experts and stakeholders, we strived to create a dynamic environment for knowledge sharing and future partnerships.

The mini-symposium was highly successful, with over 150 participants from more than 60 universities and companies. Attendees appreciated the opportunity to network and learn about the latest advancements in ATMP. The positive feedback highlights a strong interest in continued collaboration and development within this exciting field.

ATMP represents a rapidly growing sector in medicine, focusing on developing advanced therapies such as cell and gene therapies to treat previously incurable diseases. Progress in this area points toward more personalized treatments and innovative therapies that have the potential to revolutionize healthcare.

 Read more about the event here

Cellaviva: improving lives through stem cell technology

“Cellaviva was founded by researchers from Karolinska Institutet, in the belief that stem cells will revolutionize how complex and incurable diseases are treated. We are a biobank that helps expectant parents to save stem cells from the umbilical cord at birth, in a so-called family bank. The aim is to make high-quality, potent cells available quickly, if medical needs arise. This creates treatment opportunities and expands therapy options for the whole family,”

NextCell to treat type 1 diabetes in children with stem cells

NextCell Pharma in Flemingsberg has published extremely promising results from its clinical studies of drug candidate ProTrans for the treatment of type 1 diabetes. A study is now being carried out with the aim of examining its efficacy in children and young people.

Go to Top